The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling
Open accessAbstract
Background—: Endothelial dysfunction and injury are thought to play an important role in the progression of coronary artery disease (CAD). High-density lipoprotein from healthy subjects (HDL Healthy ) has been proposed to exert endothelial antiapoptotic effects that may represent an important antiatherogenic property of the lipoprotein. The present study therefore aimed to compare effects of HDL CAD and HDL Healthy on the activation of endothelial anti- and proapoptotic pathways and to determine which changes of the lipoprotein are relevant for these processes. Methods and Results—: HDL was isolated from patients with stable CAD (HDL sCAD ), an acute coronary syndrome (HDL ACS ), and healthy subjects. HDL Healthy induced expression of the endothelial antiapoptotic Bcl-2 protein Bcl-xL and reduced endothelial cell apoptosis in vitro and in apolipoprotein E–deficient mice in vivo. In contrast, HDL sCAD and HDL ACS did not inhibit endothelial apoptosis, failed to activate endothelial Bcl-xL, and stimulated endothelial proapoptotic pathways, in particular, p38-mitogen-activated protein kinase–mediated activation of the proapoptotic Bcl-2 protein tBid. Endothelial antiapoptotic effects of HDL Healthy were observed after inhibition of endothelial nitric oxide synthase and after delipidation, but not completely mimicked by apolipoprotein A-I or reconstituted HDL, suggesting an important role of the HDL proteome. HDL proteomics analyses and subsequent validations and functional characterizations suggested a reduced clusterin and increased apolipoprotein C-III content of HDL sCAD and HDL ACS as mechanisms leading to altered effects on endothelial apoptosis. Conclusions—: The present study demonstrates for the first time that HDL CAD does not activate endothelial antiapoptotic pathways, but rather stimulates potential endothelial proapoptotic pathways. HDL-proteome remodeling plays an important role for these altered functional properties of HDL. These findings provide novel insights into mechanisms leading to altered vascular effects of HDL in coronary disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike HDL from healthy subjects, HDL from patients with CHD, kidney disease or diabetes mellitus have no protective vascular effects or may even cause paradoxical harmful effects [55, 56, 61, 70, 71, 75, 76].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [75]
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,806
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Coronary Risk Factors and Plaque Morphology in Men with Coronary Disease Who Died Suddenly
BURKE, A. P., Farb, A. A., Malcom, G. T., Liang, Y.-H., Smialek, J. E., & Virmani, R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705013361802 · Cited by 1,739
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D. G., Chang, B. S., Thompson, C. B., Wong, S., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
Coronary Plaque Erosion Without Rupture Into a Lipid Core
Farb, A. A., BURKE, A. P., Tang, A. L., Liang, Y.-H., Mannan, P., Smialek, J. E., & Virmani, R. (1996) · Circulation · doi:10.1161/01.cir.93.7.1354 · Cited by 1,272
A Tale of Coronary Artery Disease and Myocardial Infarction
Nabel, E. G., & Braunwald, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112570 · Cited by 1,024
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 7×
“Similarly, by using TUNEL staining, we observed that HDL Healthy and delipidated HDL Healthy signifi- cantly reduced the number of apoptotic endothelial cells (22.2±8.0% and 19.0±14.1% versus control 37.6±10.2%, P<0.05), that was not observed with apoA-I or rHDL alone (29.0±8.7% and 25.3±10.4%, respectively; P=0.11 an…”
BackgroundInfluentialStability and Instability: Two Faces of Coronary Atherosclerosis
Davies, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.8.2013 · Cited by 923
Assessment of Culprit Lesion Morphology in Acute Myocardial Infarction
Kubo, T., Imanishi, T., Takarada, S., Kuroi, A., Ueno, S., Yamano, T., Tanimoto, T., Matsuo, Y., Masho, T., Kitabata, H., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.082 · Cited by 865
Endothelial Function: A Critical Determinant in Atherosclerosis?
Landmesser, U., Hornig, B., & Drexler, H. (2004) · Circulation · doi:10.1161/01.cir.0000129501.88485.1f · Cited by 851
Self-citationYuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L., Osborne-Lawrence, S. L., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 753
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., Wolinska, I., Lipinski, K. V. W., Baba, H. A., Tietge, U. J. F., Gödecke, A., Ishii, I., Kleuser, B., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18004 · Cited by 705
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 663
Molecular regulation of HDL metabolism and function: implications for novel therapies
Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 610
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418004 · Cited by 607
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535
Self-citationNagueh, S. F., Lakkis, N. M., Middleton, K. J., Franklin, J. L., & Spencer, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000115644.35804.8b · Cited by 425
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 1×
“ApoC-III inhibits the clearance of triglyceride-rich lipoproteins.(51) A previous study has shown that LDL containing apoC-III was independently associated with an increased risk of CAD.”
BackgroundSorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402
Self-citationIncreased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta
Caplan, B. A., & Schwartz, C. J. (1973) · Atherosclerosis · doi:10.1016/0021-9150(73)90031-2 · Cited by 380
Nofer, J., Levkau, B., Wolinska, I., Junker, R., Fobker, M., von Eckardstein, A., Seedorf, U., & Assmann, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103782200 · Cited by 359
Estrogen-Receptor–Mediated Inhibition of Human Endothelial Cell Apoptosis
Spyridopoulos, I., Sullivan, A. B., Kearney, M., Isner, J. M., & Losordo, D. W. (1997) · Circulation · doi:10.1161/01.cir.95.6.1505 · Cited by 285
Cuní, S., Pérez‐Aciego, P., Pérez-Chacón, G., Vargas, J. A., Sánchez, A., Martín-Saavedra, F. M., Ballester, S., Garcia-Marco, J. A., Jordá, J., & Durántez, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403398 · Cited by 240
Ferrante, G., Nakano, M., Prati, F., Niccoli, G., Mallus, M. T., Ramazzotti, V., Montone, R. A., Kolodgie, F. D., Virmani, R., & Crea, F. (2010) · Circulation · doi:10.1161/circulationaha.110.955302 · Cited by 237
Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage
Deverman, B. E., Cook, B. L., Manson, S. R., Niederhoff, R. A., Langer, E. M., Rosová, I., Kulans, L. A., Fu, X., Weinberg, J. S., Heinecke, J. W., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00972-8 · Cited by 235
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet
Terasaka, N., Yu, S., Yvan‐Charvet, L., Wang, N., Mzhavia, N., Langlois, R., Pagler, T. A., Li, R., Welch, C. L., Goldberg, I. J., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35470 · Cited by 232
The molecular mechanisms of the thrombotic complications of atherosclerosis
Libby, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01965.x · Cited by 226
HDL and ApoA Prevent Cell Death of Endothelial Cells Induced by Oxidized LDL
Suc, I., Escargueil‐Blanc, I., Troly, M., Salvayre, R., & Nègre‐Salvayre, A. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.2158 · Cited by 203
Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease
Sattler, K., Elbasan, Ş., Keul, P., Elter-Schulz, M., Bode, C., Gräler, M. H., Bröcker‐Preuß, M., Budde, T., Erbel, R., Heusch, G., et al. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0112-5 · Cited by 192
Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?
Dimmeler, S., Hermann, C., & Zeiher, A. M. (1998) · PubMed · Cited by 181
High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-α-Induced Apoptosis
Sugano, M., Tsuchida, K., & Makino, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2877 · Cited by 180
Apolipoprotein J Is Associated with Paraoxonase in Human Plasma
Kelso, G. J., Stuart, W. D., Richter, R. J., Furlong, C. E., Jordan, T. C., & Harmony, J. A. K. (1994) · Biochemistry · doi:10.1021/bi00169a026 · Cited by 177
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Trougakos, I. P., Poulakou, M. V., Stathatos, M., Chalikia, A., Melidonis, A. I., & Gonos, E. S. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00139-0 · Cited by 157
Charakida, M. (2009) · JAMA · doi:10.1001/jama.2009.1346 · Cited by 152
Jensen, M. K., Rimm, E. B., Furtado, J. D., & Sacks, F. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000232 · Cited by 142
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300253-jlr200 · Cited by 139
Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E., & Sacks, F. M. (2011) · Circulation · doi:10.1161/circulationaha.111.056986 · Cited by 136
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S. M., Brunzell, J. D., Knopp, R. H., Zhao, X.-Q., & Heinecke, J. W. (2008) · Circulation · doi:10.1161/circulationaha.108.770669 · Cited by 131
Souza, J. A., Vindis, C., Nègre‐Salvayre, A., Rye, K., Couturier, M., Thérond, P., Chantepie, S., Salvayre, R., Chapman, M. J., & Kontush, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00713.x · Cited by 128
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Lenten, B. J. V., Wagner, A. C., Hama, S. Y., Hough, G., Bachini, E., Garber, D. W., Mishra, V., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000174589.70190.e2 · Cited by 109
Spectral Index for Assessment of Differential Protein Expression in Shotgun Proteomics
Fu, X., Gharib, S. A., Green, P. S., Aitken, M. L., Frazer, D. A., Park, D. R., Vaisar, T., & Heinecke, J. W. (2008) · Journal of Proteome Research · doi:10.1021/pr070271+ · Cited by 108
Hoofnagle, A. N., Wu, M., Gosmanova, A. K., Becker, J. O., Wijsman, E. M., Brunzell, J. D., Kahn, S. E., Knopp, R. H., Lyons, T. J., & Heinecke, J. W. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.212894 · Cited by 87
Kim, H.-J., Yoo, E.-K., Kim, J.-Y., Choi, Y.-K., Lee, H., Kim, J.-K., Jeoung, N. H., Lee, K., Park, I.-S., Min, B.-H., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.190058 · Cited by 78
Harðardóttir, I., Kunitake, S. T., Moser, A. H., Doerrler, W. T., Rapp, J. H., Grünfeld, C., & Feingold, K. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117449 · Cited by 72
Antiinflammatory Actions of HDL
Rye, K., & Barter, P. J. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.173575 · Cited by 70
Dallinga‐Thie, G. M., Berk-Planken, I. I. L., Bootsma, A. H., Jansen, H., & on behalf of the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1358 · Cited by 51
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50
Ooi, E. M. M., Watts, G. F., Chan, D. C., Chen, M., Nestel, P. J., Sviridov, D., & Barrett, P. H. R. (2008) · Diabetes Care · doi:10.2337/dc08-0358 · Cited by 41
Structure and stability of apolipoprotein J-containing high-density lipoproteins
Stuart, W. D., Krol, B. J., Jenkins, S. H., & Harmony, J. A. K. (1992) · Biochemistry · doi:10.1021/bi00151a024 · Cited by 38
Nguyen, M. N., Chan, D. C., Dwyer, K. P., Bolitho, P., Watts, G. F., & Barrett, P. H. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600018-jlr200 · Cited by 23
Research works printed but not linked: 1
- 10.1021/pr070271 · DOI
Cited by
Sorted by citations
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease
Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603
“ApoA-I and HDL are well established to protect endothelial function and promote endothelial repair in large peripheral vessels [48–50], and are also reported to affect activity of the innate immune system and provide antiinflammatory and antioxidant functions [48,49,51].”
BackgroundSoppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
“the latter, apoC-III interferes with the capacity of HDL to inhibit the apoptosis of endothelial cells and to promote efflux from macrophages and SAA disturbs HDL’s ability to activate eNOS.(107,109) As integrative measures of HDL function, also bioassays were validated in population and clinical studies.”
BackgroundHDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research
Rohatgi, A. K., Westerterp, M., von Eckardstein, A., Remaley, A. T., & Rye, K. (2021) · Circulation · doi:10.1161/circulationaha.120.044221 · Cited by 353
Metadata
- Authors
- Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., Lüscher, T. F., & Landmesser, U.
- Affiliations
- University of Zurich (CH)
- From Cardiology, Cardiovascular Center, University Hospital Zurich, Switzerland (M.R., C.B., P.M., M.M., K.H., L.A., T.F.L., U.L.); Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland (M.R., C.B., P.M., K.H., L.A., T.F.L., U.L.); Center for Integrative Human Physiology, University of Zurich, Switzerland (M.R., L.R., C.B., L.A., A.v.E., T.F.L., U.L.); Institute of Clinical Chemistry, University Hospital Zurich, Switzerland (L.R., A.v.E.); and Functional Genomics Center...
- ORCID
- Venue
- Circulation
- Published
- 2013-02-26
- Volume
- 127
- Issue
- 8
- Pages
- 891-904
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2769328074
- Cited by
- 337
- References
- 58
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 25 · 2021: 22 · 2020: 19 · 2019: 35 · 2018: 30 · 2017: 29 · 2016: 26 · 2015: 42 · 2014: 41 · 2013: 29
- FWCI
- 25.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.zora.uzh.ch
- Licence
- other-oa
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- high-density lipoprotein, coronary artery disease, endothelial cell apoptosis, Bcl-xL, tBid, p38 MAPK, clusterin, apolipoprotein C-III, HDL proteome, endothelial dysfunction, acute coronary syndrome, ApoE-deficient mice, nitric oxide synthase, anti-apoptotic pathways
- MeSH terms
- Animals, Apolipoproteins E, Coronary Artery Disease, Endothelium, Vascular, Female, Flow Cytometry, Humans, Lipoproteins, HDL, Male, Mice, Inbred C57BL, Middle Aged, Signal Transduction, Apoptosis, Mice, Knockout, Proteome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review